Jingfeng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingfeng Zhou has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Zhongsong Zhang
The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, China
7 shared publications - Junhao Chen
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
6 shared publications - Keyi Gou
Department of Gastrointestinal Surgery, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
6 shared publications - Junxian Zhao
Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Kunming, Yunnan, People’s Republic of China
5 shared publications Shi Fu
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, 650032, People’s Republic of China
3 shared publications- Chengjie Wang
School of Stomatology, Xinjiang Second Medical College, Karamay, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-41
Precision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling
Lung cancer remains one of the most prevalent and lethal malignancies worldwide and is characterized by a complex tumor microenvironment (TME), including severe hypoxia, acidosis, elevated glutathione levels, and pronounced immunosuppression. These pathological conditions compromise the efficacy of conventional therapies and contribute to drug resistance, tumor recurrence, and metastasis. Nanodynamic therapy (NDT) is an emerging therapeutic paradigm that employs nanomaterials to amplify reactive oxygen species (ROS) generation in response to endogenous or exogenous stimuli, thereby enabling localized tumor ablation and immune reprogramming. This review systematically summarizes the biological basis of NDT in lung cancer. Particular emphasis is placed on the sequential biological processes of TME responsiveness, programmed cell death (PCD) pathway reprogramming, and immune remodeling. We comprehensively review the therapeutic applications and translational potential of four major NDT modalities—sonodynamic therapy (SDT), chemodynamic therapy (CDT), photodynamic therapy (PDT), and radiodynamic therapy (RDT)—in lung cancer. We further highlight recent advances in the integration of these modalities with lung cancer–specific therapeutic strategies. These advances include immunogenic cell death (ICD)-mediated conversion of immunologically "cold” tumors into "hot” tumors, as well as synergistic strategies incorporating EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, anti-angiogenic treatment, and inhalable pulmonary delivery systems. Finally, we critically examine major barriers to the clinical translation of NDT, including the limited availability of clinically relevant in situ models, inadequate material consistency, insufficient long-term pulmonary toxicity data, and the lack of standardized physical activation parameters. We further propose priorities for future research and clinical translation. Collectively, this review provides a systematic and integrative framework for lung cancer NDT, spanning mechanistic design, therapeutic optimization, and potential clinical translation.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-41
Open AccessPrecision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling
Lung cancer remains one of the most prevalent and lethal malignancies worldwide and is characterized by a complex tumor microenvironment (TME), including severe hypoxia, acidosis, elevated glutathione levels, and pronounced immunosuppression. These pathological conditions compromise the efficacy of conventional therapies and contribute to drug resistance, tumor recurrence, and metastasis. Nanodynamic therapy (NDT) is an emerging therapeutic paradigm that employs nanomaterials to amplify reactive oxygen species (ROS) generation in response to endogenous or exogenous stimuli, thereby enabling localized tumor ablation and immune reprogramming. This review systematically summarizes the biological basis of NDT in lung cancer. Particular emphasis is placed on the sequential biological processes of TME responsiveness, programmed cell death (PCD) pathway reprogramming, and immune remodeling. We comprehensively review the therapeutic applications and translational potential of four major NDT modalities—sonodynamic therapy (SDT), chemodynamic therapy (CDT), photodynamic therapy (PDT), and radiodynamic therapy (RDT)—in lung cancer. We further highlight recent advances in the integration of these modalities with lung cancer–specific therapeutic strategies. These advances include immunogenic cell death (ICD)-mediated conversion of immunologically "cold” tumors into "hot” tumors, as well as synergistic strategies incorporating EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, anti-angiogenic treatment, and inhalable pulmonary delivery systems. Finally, we critically examine major barriers to the clinical translation of NDT, including the limited availability of clinically relevant in situ models, inadequate material consistency, insufficient long-term pulmonary toxicity data, and the lack of standardized physical activation parameters. We further propose priorities for future research and clinical translation. Collectively, this review provides a systematic and integrative framework for lung cancer NDT, spanning mechanistic design, therapeutic optimization, and potential clinical translation.
- Open Access
- 23 August 2026
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 17 (1)
Multimodal nanomedicine for precision colorectal cancer management: integrated diagnosis, targeted therapy, and personalized theranostics
- 23 August 2026
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 17 (1)
Open AccessMultimodal nanomedicine for precision colorectal cancer management: integrated diagnosis, targeted therapy, and personalized theranostics
- Open Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-35
The Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention
Kidney stone disease is one of the most common urologic disorders worldwide and imposes a growing clinical and socioeconomic burden because of its rising prevalence, high recurrence rate, and association with chronic kidney injury and systemic metabolic abnormalities. Calcium oxalate (CaOx) stones remain the predominant stone type, and their formation is now recognized as a multistep process involving urinary supersaturation, crystal nucleation and growth, tubular epithelial injury, oxidative stress, inflammation, and crystal retention. Although current management strategies, including dietary modification, pharmacologic prevention, and endourologic interventions, have substantially improved stone clearance, important limitations remain. These include inadequate early detection, suboptimal prevention of recurrence, insufficient targeting of the local renal microenvironment, and procedure-related complications. Recent advances in nanotechnology offer new opportunities to address these unmet needs. Owing to their large specific surface area, tunable physicochemical properties, versatile surface functionalization, and capacity for multimodal integration, nanomaterials have shown considerable promise in metabolic sensing, urinary biomarker detection, targeted drug delivery, modulation of crystal growth, biomimetic renal targeting, and photothermal or photoresponsive lithotripsy. In parallel, the convergence of nanotechnology with artificial intelligence, smart diagnostic devices, and personalized metabolic profiling is reshaping kidney stone management. This shift is moving the field from passive stone removal toward active risk prediction, dynamic monitoring, and precision prevention. In this review, we summarize recent advances in nanomaterial-based strategies for the diagnosis, treatment, and prevention of kidney stones, with particular emphasis on CaOx disease. We also discuss the major translational barriers, including biocompatibility, long-term safety, regulatory complexity, scalable manufacturing, and cost-effectiveness, and outline future directions for clinically integrated, intelligent, and individualized stone care.
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-35
Open AccessThe Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention
Kidney stone disease is one of the most common urologic disorders worldwide and imposes a growing clinical and socioeconomic burden because of its rising prevalence, high recurrence rate, and association with chronic kidney injury and systemic metabolic abnormalities. Calcium oxalate (CaOx) stones remain the predominant stone type, and their formation is now recognized as a multistep process involving urinary supersaturation, crystal nucleation and growth, tubular epithelial injury, oxidative stress, inflammation, and crystal retention. Although current management strategies, including dietary modification, pharmacologic prevention, and endourologic interventions, have substantially improved stone clearance, important limitations remain. These include inadequate early detection, suboptimal prevention of recurrence, insufficient targeting of the local renal microenvironment, and procedure-related complications. Recent advances in nanotechnology offer new opportunities to address these unmet needs. Owing to their large specific surface area, tunable physicochemical properties, versatile surface functionalization, and capacity for multimodal integration, nanomaterials have shown considerable promise in metabolic sensing, urinary biomarker detection, targeted drug delivery, modulation of crystal growth, biomimetic renal targeting, and photothermal or photoresponsive lithotripsy. In parallel, the convergence of nanotechnology with artificial intelligence, smart diagnostic devices, and personalized metabolic profiling is reshaping kidney stone management. This shift is moving the field from passive stone removal toward active risk prediction, dynamic monitoring, and precision prevention. In this review, we summarize recent advances in nanomaterial-based strategies for the diagnosis, treatment, and prevention of kidney stones, with particular emphasis on CaOx disease. We also discuss the major translational barriers, including biocompatibility, long-term safety, regulatory complexity, scalable manufacturing, and cost-effectiveness, and outline future directions for clinically integrated, intelligent, and individualized stone care.
- Top Cited PapersOpen Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-33
Exosome-Mediated Rewiring of Oxidative Stress–Inflammation–ECM Remodeling Axis Mitigates UVB-Triggered Skin Photoaging
Photoaging is a chronic and multifactorial form of skin aging primarily induced by ultraviolet (UV) radiation. It is characterized by oxidative stress, DNA damage, chronic inflammation, pigmentary alterations, and extracellular matrix (ECM) degradation, which ultimately lead to wrinkle formation, loss of elasticity, and uneven pigmentation. Exosomes, nanosized extracellular vesicles that mediate intercellular communication, have attracted growing attention in photoaging research. Emerging evidence suggests that exosomes may both contribute to photoaging and promote tissue repair by modulating cellular responses. However, despite the growing body of evidence, the field still lacks an integrated review that links exosome biogenesis and functional properties to the mechanisms of photoaging, their therapeutic potential, and the major translational barriers to clinical application. Therefore, this review aims to systematically summarize the biogenesis and biological properties of exosomes, clarify their mechanistic roles in photoaging, particularly in the regulation of oxidative stress, and evaluate their potential as therapeutic agents and delivery platforms for anti-photoaging and regenerative medicine. It further examines the effects of native exosomes derived from multiple cell sources, with a focus on stem cells, keratinocytes, and melanocytes. Finally, it outlines translational opportunities for exosome-based interventions in anti-photoaging and regenerative medicine, including engineered exosome mimetics and other nanomedicine-based strategies. It also highlights the key knowledge gaps and technical challenges that must be addressed to facilitate clinical translation. In conclusion, exosomes represent a promising yet still evolving strategy for the prevention and treatment of photoaging because of their dual roles in intercellular signaling and tissue regeneration. Nevertheless, further standardization of isolation, characterization, engineering, safety assessment, and regulatory evaluation is essential before their full clinical potential can be realized.
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-33
Top Cited PapersOpen AccessExosome-Mediated Rewiring of Oxidative Stress–Inflammation–ECM Remodeling Axis Mitigates UVB-Triggered Skin Photoaging
Photoaging is a chronic and multifactorial form of skin aging primarily induced by ultraviolet (UV) radiation. It is characterized by oxidative stress, DNA damage, chronic inflammation, pigmentary alterations, and extracellular matrix (ECM) degradation, which ultimately lead to wrinkle formation, loss of elasticity, and uneven pigmentation. Exosomes, nanosized extracellular vesicles that mediate intercellular communication, have attracted growing attention in photoaging research. Emerging evidence suggests that exosomes may both contribute to photoaging and promote tissue repair by modulating cellular responses. However, despite the growing body of evidence, the field still lacks an integrated review that links exosome biogenesis and functional properties to the mechanisms of photoaging, their therapeutic potential, and the major translational barriers to clinical application. Therefore, this review aims to systematically summarize the biogenesis and biological properties of exosomes, clarify their mechanistic roles in photoaging, particularly in the regulation of oxidative stress, and evaluate their potential as therapeutic agents and delivery platforms for anti-photoaging and regenerative medicine. It further examines the effects of native exosomes derived from multiple cell sources, with a focus on stem cells, keratinocytes, and melanocytes. Finally, it outlines translational opportunities for exosome-based interventions in anti-photoaging and regenerative medicine, including engineered exosome mimetics and other nanomedicine-based strategies. It also highlights the key knowledge gaps and technical challenges that must be addressed to facilitate clinical translation. In conclusion, exosomes represent a promising yet still evolving strategy for the prevention and treatment of photoaging because of their dual roles in intercellular signaling and tissue regeneration. Nevertheless, further standardization of isolation, characterization, engineering, safety assessment, and regulatory evaluation is essential before their full clinical potential can be realized.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-36
Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy
Colorectal cancer (CRC) is a common malignancy that remains difficult to control with surgery, chemotherapy, radiotherapy, and targeted therapy. These challenges arise from tumor heterogeneity, therapy resistance, and frequent relapse or metastasis, especially in advanced disease. In addition, precision approaches are limited by interpatient variability, evolving targets, and suboptimal biomarker performance. Nanodynamic therapy (NDT) is a modular, energy-activated strategy (e.g. PDT, SDT, CDT, and EDT). It can be systematically engineered using a “Structure–Energy Conversion–Reaction Dynamics” framework that links nanoplatform architecture to stimulus-transduction efficiency and spatiotemporally controlled cytotoxic reactions. NDT converts externally applied light, ultrasound, or electric fields into localized oxidative or catalytic cytotoxicity, potentially reducing off-target injury. This approach is particularly relevant to CRC because intracavitary or endoluminal energy delivery enables precise spatiotemporal control that is difficult to achieve with systemic targeting alone. However, NDT alone rarely addresses the full complexity of the heterogeneous, immunosuppressive CRC microenvironment. Efficacy is often limited by hypoxia, immunologically “cold” tumors, and suboptimal synchronization of treatment timing and delivery. These constraints motivate rational combinations with immunotherapy and microenvironment-targeted interventions. In this review, we summarize organ-specific design principles for CRC-focused NDT. Guided by the Structure–Energy Conversion–Reaction Dynamics paradigm, we describe how nanostructure design (e.g. composition, morphology, and interfaces) governs energy deposition and conversion. We then explain how these processes shape ROS/catalytic kinetics and diffusion, and how the resulting dynamics can be tuned for CRC-relevant activation routes. We further discuss how programmable, locally activated modules can be integrated into synergistic regimens that couple tumor debulking and immunogenic cell death with durable immune programming. We also highlight localized hydrogel- or depot-based “logistics layers” that maintain high drug concentrations at resection margins or intraperitoneal sites. These platforms enable repeated external triggering and coordinated multiagent release, helping to overcome systemic co-delivery barriers. Finally, we outline translational priorities, including patient stratification and biomarkers, clinically compatible energy delivery, manufacturability, and tumor access constraints. These considerations may guide the development of CRC-ready NDT platforms toward prospective validation.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-36
Open AccessNanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy
Colorectal cancer (CRC) is a common malignancy that remains difficult to control with surgery, chemotherapy, radiotherapy, and targeted therapy. These challenges arise from tumor heterogeneity, therapy resistance, and frequent relapse or metastasis, especially in advanced disease. In addition, precision approaches are limited by interpatient variability, evolving targets, and suboptimal biomarker performance. Nanodynamic therapy (NDT) is a modular, energy-activated strategy (e.g. PDT, SDT, CDT, and EDT). It can be systematically engineered using a “Structure–Energy Conversion–Reaction Dynamics” framework that links nanoplatform architecture to stimulus-transduction efficiency and spatiotemporally controlled cytotoxic reactions. NDT converts externally applied light, ultrasound, or electric fields into localized oxidative or catalytic cytotoxicity, potentially reducing off-target injury. This approach is particularly relevant to CRC because intracavitary or endoluminal energy delivery enables precise spatiotemporal control that is difficult to achieve with systemic targeting alone. However, NDT alone rarely addresses the full complexity of the heterogeneous, immunosuppressive CRC microenvironment. Efficacy is often limited by hypoxia, immunologically “cold” tumors, and suboptimal synchronization of treatment timing and delivery. These constraints motivate rational combinations with immunotherapy and microenvironment-targeted interventions. In this review, we summarize organ-specific design principles for CRC-focused NDT. Guided by the Structure–Energy Conversion–Reaction Dynamics paradigm, we describe how nanostructure design (e.g. composition, morphology, and interfaces) governs energy deposition and conversion. We then explain how these processes shape ROS/catalytic kinetics and diffusion, and how the resulting dynamics can be tuned for CRC-relevant activation routes. We further discuss how programmable, locally activated modules can be integrated into synergistic regimens that couple tumor debulking and immunogenic cell death with durable immune programming. We also highlight localized hydrogel- or depot-based “logistics layers” that maintain high drug concentrations at resection margins or intraperitoneal sites. These platforms enable repeated external triggering and coordinated multiagent release, helping to overcome systemic co-delivery barriers. Finally, we outline translational priorities, including patient stratification and biomarkers, clinically compatible energy delivery, manufacturability, and tumor access constraints. These considerations may guide the development of CRC-ready NDT platforms toward prospective validation.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-32
Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Advanced stages are characterized by tumor heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs), the predominant stromal cells in the PCa tumor microenvironment (TME), critically drive tumor progression, metastasis, and therapeutic resistance. Nanomedicine represents a transformative strategy for targeting CAFs. It leverages engineered nanomaterials to achieve precise drug delivery, improved bioavailability, and multimodal theranostic capabilities, which integrate diagnosis with therapy. This review comprehensively examines advances in nanomaterial-based strategies for CAF-targeted therapy in PCa. We first delineate the biology of CAFs in PCa, encompassing their origins, activation mechanisms, key markers (e.g, α-SMA and FAP), phenotypic heterogeneity, and intricate crosstalk with cancer cells, immune cells, and the extracellular matrix (ECM). We then evaluate nanomaterial-based targeting strategies and therapeutic modalities, including CAF depletion, reprogramming, and extracellular matrix remodeling, for the treatment of PCa. Subsequently, we discuss CAF-targeted nanoplatforms for theranostics, including molecular imaging probes (e.g., 68Ga-FAPI) and image-guided delivery systems that integrate precise diagnosis with therapy. Finally, we address key challenges, particularly CAF heterogeneity and nanomaterial biosafety, and outline future directions, including gene-editing integration, multi-stimuli-responsive systems, and synergistic immunotherapy combinations. Collectively, this review underscores the transformative potential of integrating CAF biology with nanotechnology to overcome therapeutic resistance in PCa and advance precision oncology.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-32
Open AccessNanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Advanced stages are characterized by tumor heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs), the predominant stromal cells in the PCa tumor microenvironment (TME), critically drive tumor progression, metastasis, and therapeutic resistance. Nanomedicine represents a transformative strategy for targeting CAFs. It leverages engineered nanomaterials to achieve precise drug delivery, improved bioavailability, and multimodal theranostic capabilities, which integrate diagnosis with therapy. This review comprehensively examines advances in nanomaterial-based strategies for CAF-targeted therapy in PCa. We first delineate the biology of CAFs in PCa, encompassing their origins, activation mechanisms, key markers (e.g, α-SMA and FAP), phenotypic heterogeneity, and intricate crosstalk with cancer cells, immune cells, and the extracellular matrix (ECM). We then evaluate nanomaterial-based targeting strategies and therapeutic modalities, including CAF depletion, reprogramming, and extracellular matrix remodeling, for the treatment of PCa. Subsequently, we discuss CAF-targeted nanoplatforms for theranostics, including molecular imaging probes (e.g., 68Ga-FAPI) and image-guided delivery systems that integrate precise diagnosis with therapy. Finally, we address key challenges, particularly CAF heterogeneity and nanomaterial biosafety, and outline future directions, including gene-editing integration, multi-stimuli-responsive systems, and synergistic immunotherapy combinations. Collectively, this review underscores the transformative potential of integrating CAF biology with nanotechnology to overcome therapeutic resistance in PCa and advance precision oncology.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 18079-18113
The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which intense pruritus and eczematous lesions arise from tightly coupled disturbances of the nervous and immune systems. Emerging evidence indicates that a dysregulated neuroimmune axis—as reflected by peripheral neuronal sensitization, epidermal barrier dysfunction, and central itch processing—plays a central role in disease onset, persistence, and clinical heterogeneity. In this review, we synthesize current knowledge on the neuroimmune mechanisms that drive AD, focusing on how cytokines such as IL-31, IL-4/IL-13, TSLP and IL-33, together with neuropeptides including substance P, CGRP and VIP, establish self-reinforcing itch–scratch and inflammation loops at the level of the skin and the central nervous system. We then highlight recent multi-omics and systems biology approaches, including single-cell and spatial transcriptomics, neuroimaging, and microbiome profiling, that have reshaped the understanding of neuroimmune “neighbourhoods” and the gut–skin–brain axis in AD. Building on these mechanistic insights, we summarize key neuroimmune biomarkers—such as NGF, IL-31, TARC/CCL17, S100 proteins, barrier-related lipids, neurofunctional readouts from fMRI, and microbial signatures—and discuss their potential for improving diagnosis, patient stratification, and treatment monitoring within a precision medicine framework. Finally, we review established and emerging neuroimmune-targeted therapies, including IL-4/IL-13 and IL-31 pathway inhibitors, JAK inhibitors, OX40/OX40L-directed biologics, TRP and NK1R antagonists, phototherapy, and microbiome-based interventions, with a particular emphasis on biomarker-guided sequencing and combination strategies. Overall, we propose that positioning the neuroimmune axis at the core of AD pathogenesis provides a conceptual basis for developing stratified, durable, and patient-centred neuroimmunotherapy, while also outlining the remaining challenges regarding clinical validation of biomarkers, long-term safety, accessibility, and implementation across diverse patient populations.
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 18079-18113
Open AccessThe Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which intense pruritus and eczematous lesions arise from tightly coupled disturbances of the nervous and immune systems. Emerging evidence indicates that a dysregulated neuroimmune axis—as reflected by peripheral neuronal sensitization, epidermal barrier dysfunction, and central itch processing—plays a central role in disease onset, persistence, and clinical heterogeneity. In this review, we synthesize current knowledge on the neuroimmune mechanisms that drive AD, focusing on how cytokines such as IL-31, IL-4/IL-13, TSLP and IL-33, together with neuropeptides including substance P, CGRP and VIP, establish self-reinforcing itch–scratch and inflammation loops at the level of the skin and the central nervous system. We then highlight recent multi-omics and systems biology approaches, including single-cell and spatial transcriptomics, neuroimaging, and microbiome profiling, that have reshaped the understanding of neuroimmune “neighbourhoods” and the gut–skin–brain axis in AD. Building on these mechanistic insights, we summarize key neuroimmune biomarkers—such as NGF, IL-31, TARC/CCL17, S100 proteins, barrier-related lipids, neurofunctional readouts from fMRI, and microbial signatures—and discuss their potential for improving diagnosis, patient stratification, and treatment monitoring within a precision medicine framework. Finally, we review established and emerging neuroimmune-targeted therapies, including IL-4/IL-13 and IL-31 pathway inhibitors, JAK inhibitors, OX40/OX40L-directed biologics, TRP and NK1R antagonists, phototherapy, and microbiome-based interventions, with a particular emphasis on biomarker-guided sequencing and combination strategies. Overall, we propose that positioning the neuroimmune axis at the core of AD pathogenesis provides a conceptual basis for developing stratified, durable, and patient-centred neuroimmunotherapy, while also outlining the remaining challenges regarding clinical validation of biomarkers, long-term safety, accessibility, and implementation across diverse patient populations.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 3083-3084
Letter to the Editor Regarding “Effect of Propofol on Postoperative Sleep Quality in Patients Undergoing Elective Cesarean Section with Spinal Anesthesia: A Retrospective Cohort Study Using Propensity Score Matching at a Single Center” [Letter]
Letter for the article Effect of Propofol on Postoperative Sleep Quality in Patients Undergoing Elective Cesarean Section with Spinal Anesthesia:A Retrospective Cohort Study Using Propensity Score Matching at a Single Center
- 1 November 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 3083-3084
Open AccessLetter to the Editor Regarding “Effect of Propofol on Postoperative Sleep Quality in Patients Undergoing Elective Cesarean Section with Spinal Anesthesia: A Retrospective Cohort Study Using Propensity Score Matching at a Single Center” [Letter]
Letter for the article Effect of Propofol on Postoperative Sleep Quality in Patients Undergoing Elective Cesarean Section with Spinal Anesthesia:A Retrospective Cohort Study Using Propensity Score Matching at a Single Center